-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On July 27, 2021, Sol-Gel Technologies announced that the US FDA has approved its innovative combination therapy Twyneo cream for the treatment of acne vulgaris (acne vulgaris) in adults and children aged 9 years and older
Acne vulgaris is a common multifactorial skin disease that most commonly occurs in children and adolescents, affecting 80%-85% of adolescents, but it may also occur in adults
Tretinoin and benzoyl peroxide are widely used in the treatment of acne vulgaris, respectively.
▲Sol-Gel's microencapsulated drug delivery technology (picture source: Sol-Gel's official website)
The approval is based on the positive results of two randomized, double-blind, excipient-controlled, multi-center Phase 3 clinical trials
Note: The original text has been deleted
Reference materials:
[1] Sol-Gel Technologies Announces FDA Approval of TWYNEO.